Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML).

Abstract

AIDS-related PML continues to be a relatively common and rapidly fatal infection in patients with AIDS, and no effective therapy has been established to alleviate the effects of this disease. Through the years, isolated reports and small case studies have shown somewhat encouraging results using cytosine arabinoside (AraC) in the treatment of PML. The optimism behind the use AraC for this disease began to fade with ACTG trial 243, which suggested that AraC had no benefit in patients with HIV-related PML. In this article, we provide evidence that suggests that the failure of AraC in the ACTG trial may have been due to insufficient delivery of the drug through traditional intravenous and intrathecal routes. Furthermore, we provide evidence that convection-enhanced intraparenchymal delivery of AraC may prove to be a safe and effective means of treating this infection, and we outline a clinical trial that we have recently undertaken to test this hypothesis.

• Authors: R M Levy, E Major, M J Ali, B Cohen, D Groothius
• Journal: Journal of neurovirology (J Neurovirol) Vol. 7 Issue 4 Pg. 382-5 (Aug 2001) ISSN: 1355-0284 [Print] United States
• PMID: 11517421 (Publication Type: Journal Article, Review)

Chemical References

• Antiviral Agents
• Cytarabine

Topics

• AIDS-Related Opportunistic Infections (drug therapy)
• Animals
• Antiviral Agents (pharmacology)
• Cytarabine (pharmacokinetics)
• Drug Delivery Systems (methods)
• Humans
• Leukoencephalopathy, Progressive Multifocal (drug therapy)